Recovery from cortical blindness with mepivacaïne
Laurent Cohen, Amélie Ponchel, Aurélie Kas, Sebastian Stroer, Antoine Cul, Guillaume Guérineau de Lamérie, Randa El Hachem, Piirika Crépin, Alexandre Morin

To cite this version:
Laurent Cohen, Amélie Ponchel, Aurélie Kas, Sebastian Stroer, Antoine Cul, et al.. Recovery from cortical blindness with mepivacaïne. Annals of Clinical and Translational Neurology, Wiley, 2019, 6 (8), pp.1541-1545. 10.1002/acn3.50832 . hal-02279804
Recovery from cortical blindness with mepivacaïne

Laurent Cohen1,2, Amélie Ponchet1,2, Aurélie Kas3, Sébastien Ströer4, Antoine Del Cul5, Guillaume Guérineau de Lamérie6, Randa El Hachem7, Piirika Crépin8 & Alexandre Morin2

1Institut du Cerveau et de la Moelle épinière, ICM, Sorbonne Université, Inserm U 1127, CNRS UMR 7225, F-75013 Paris, France
2Département de neurologie, Hôpital de la Pitié Salpêtrière, AP-HP, F-75013 Paris, France
3Service de médecine nucléaire, Hôpital de la Pitié Salpêtrière, AP-HP, F-75013 Paris, France
4Service de neuroradiologie, Hôpital de la Pitié Salpêtrière, AP-HP, F-75013 Paris, France
5Service de psychiatrie, Hôpital de la Pitié Salpêtrière, AP-HP, F-75013 Paris, France
6Département d’information médicale, Centre hospitalier Guillaume Régnier, 35703 Rennes, France
7Service d’anesthésie, Centre Hospitalier, 11100 Narbonne, France
8Centre Medico Psycho Pédagogique, 11100 Narbonne, France

Correspondence
Laurent Cohen, Département de neurologie, Hôpital de la Pitié Salpêtrière, AP-HP, F-75013 Paris, France. Tel: +00 331 475 74315; Fax: +00 331 421 61807; E-mail: laurentcohen2@gmail.com

Funding Information
This study was funded by the “Investissements d’avenir” program (ANR-10-IHU-06) to the Brain and Spine Institute.

Abstract
We report the case of a patient suffering from cortical blindness following bilateral occipital stroke, who recovered normal vision in his right visual field following injection of the local anesthetic mepivacaïne. The effect was transient but reproducible, allowing the patient to lead a normal life. Effect duration increased after adjunction of paroxetine. We provide anatomical and functional brain imaging correlates of this improvement, showing particularly how functional connectivity is restored between intact perilesional cortex and distant brain regions. This serendipitous finding may potentially benefit patients suffering from visual but also nonvisual handicap following brain lesions.

Introduction
Stroke is a major public health problem and a frequent cause of severe sensorimotor and cognitive handicap. Poststroke rehabilitation mainly resorts to training and occupational methods, supplemented by appropriate technical devices, while drugs have shown very limited efficacy.1,2 This general dearth of effective treatments also concerns visual field loss, which affects about 30% of stroke survivors.3 We report the case of a patient suffering from almost complete cortical blindness following bilateral occipital stroke, who recovered normal vision in his right visual field following injection of the local anesthetic mepivacaïne.

Medical History
A 52-year-old man underwent surgery for a herniated cervical disc. Following surgery, he suffered from dissection of a vertebral artery, resulting in bilateral occipital infarcts, and cortical blindness. He was subsequently cared for in an institution for the rehabilitation of the blind. Two to four years later, he underwent two minor interventions on his left upper limb, under brachial plexus block with mepivacaïne, an amino-amide anesthetic. In both instances, the right hemianopia disappeared a few minutes after the anesthesia, and relapsed 3 days later. After informal testing against placebo, the patient took systematic injections of mepivacaïne (54 mg), self-injected subcutaneously upon each relapse of cortical blindness. This allowed him to live a normal life, including tinkering, gardening, and reading. The patient recorded the duration of the effect of injections over a period of 2 years (Fig. S1). To treat moderate anxiety, the patient received paroxetine starting 9 months after the onset of the logging, which doubled the mean duration from 7.4 to 15.2 days (t = 3.8, P < 0.001), with an increase in variability from SD = 2.0 to SD = 10.3 days (F = 26.4, P < 0.001).
Clinical Status
During off periods, on confrontation and using Humphrey automated perimetry, there was complete blindness except for a small region in the right periphery. During on periods, the whole right hemifield returned to normal, while hemianopia persisted in the left hemifield (Fig. 1A). An extensive battery of tests of high-level vision and general cognition performed during on periods were normal (Table S1). General neurological and psychiatric examination was normal.

Brain Imaging
All details on anatomical and functional imaging methods are provided as Data S1.
Anatomical MR images showed an infarct affecting most of the right calcarine cortex, causing the permanent left hemianopia. There was a much smaller left occipital infarct with underlying white matter hyperintensity (Fig. 1B). A study of hemifield activation with functional MRI and visual evoked potentials was unfortunately not performed.

Right-sided vision recovery suggested restoration of function in the left occipital cortex, which we assessed with resting state functional MRI, a technique used to evaluate correlations across brain regions during rest, and to infer patterns of distant interactions. First, we studied the changes in correlation induced by treatment with no anatomical a priori. Global Correlation, that is, the average correlation with the rest of the brain, increased bilaterally in the intact occipital and occipitotemporal cortex (Fig. 1C). Second, we assessed specifically the changes in the connectivity of the left calcarine cortex (Fig. 1D). There was an increase in correlation with bilateral frontoparietal regions, a network controlling attention to external events. Conversely, there was a decrease in correlation with the so-called default-mode network, involved in internally oriented cognition. As a control, we checked that the right-hemispheric calcarine region showed negligible changes in correlation (Fig. S1).

Finally, we assessed metabolic changes under mepivacaine with 18FDG PET scan. Off-mepivacaine, there was low metabolism in the areas lesioned on anatomical MRI, extending to apparently intact left occipital regions (Figs. S1 and S2 and Table S2). On-mepivacaine, there was a left-predominant decrease in the volume of low metabolism (39% and 13% decrease in the left and right occipital lobes, respectively), while the hypometabolic clusters in anatomically intact cortex returned to normal. In the absence of control subjects receiving mepivacaine, a statistical comparison of metabolic changes between the patient and controls was not possible.

Discussion
The mechanisms of the visual improvement which we observed under mepivacaine is currently unknown. Still this unexpected effect is conceivable considering the properties of mepivacaine, an amino-amide commonly used as a locoregional anesthetic.

Nature of the deficit
One may ask whether the reversible right hemianopia actually consisted in hemispatial neglect, which may also be improved with pharmacological agents. However, this hypothesis receives little support in the present case. First, during off periods, the patient did not display any kind of asymmetry in his perceptual and motor behavior. Second, the topography of the right hemianopia was not consistent with neglect, as the spared region was located in the right periphery, while in neglect the right periphery would show the most severe deficit. Third, the lesion was restricted to low-level visual cortex, sparing all areas associated with spatial neglect.

Mechanism of action
Amino-amides primarily inhibit nerve conduction by binding to and inactivating sodium channels. However, they also modulate the activity of potassium and calcium channels, including NMDA receptors, and their effects may indeed last longer than predicted from the kinetics of sodium channel blocking. They pass the blood-brain barrier, as illustrated by central neurological side effects, including drowsiness, tremor, and seizures, which however do not occur with normal doses. Note that mepivacaine is among the amino-amides with the highest CNS concentration and free brain exposure.

There is rich evidence that stroke lesions cause changes in long-range functional network connections. In the present case, PET-scan and resting-state fMRI showed that mepivacaine triggered some increase in perilesional metabolism, and the restoration of functional connections between the visual cortex and remote areas, subtending the visual improvement. This effect may be considered as the correction of a diachisis, that is, of the deactivation of intact brain regions remote from but connected to the area of primary injury, including metabolic depression in visual cortices following lesions to the optic radiations.
Figure 1. (A) Humphrey visual field assessment. During off periods (top row), there was complete blindness, except in a small right peripheral area (white arrows). On mepivacaine (bottom row), vision returned to normal in the right hemifield. (B) Anatomical FLAIR image, showing a large right mesial (solid arrows) and a smaller left ventral mesial (dotted arrows) occipital infarcts. On axial slices, the left hemisphere is shown on the left (neurological convention). (C) Bilateral increase in Global Correlation in most of the intact occipital and temporal cortex, during on- minus off-mepivacaine states. There was also an increase in prefrontal regions. (D) Increased correlation between the dysfunctional left calcarine region (white) and an attentional fronto-parietal network (hot), and decreased correlation with the default-mode network (cold), during on- minus off-mepivacaine states. Color scales represent Z scores.
Effect duration
In the present case, before adjunction of paroxetine, the visual effect of mepivacaine was longer than expected on the basis of its half-life of 4–5 h, as measured during regional anesthesia. However, such discordance between short half-life and long clinical effects is not unusual, and has been related to the complex kinetics of tissue distribution, and to the cellular mechanisms of action. Thus, nicotinic receptor agonists have enduring cognitive effects out of proportion with their short half-life, due to their induction of Long Term Potentiation phenomena. As to the shortening of the effect by physical and psychological stress, it fits with the multiple consequences of stress and effort on pharmacokinetics and brain function.

Role of paroxetine
Inhibitors of serotonin reuptake enhance motor recovery after stroke, an effect which seems independent from the doubling of the mean mepivacaine effect duration under paroxetine. This doubling likely results from the potent inhibition by paroxetine of P450 cytochromes, which degrade amido-amines. Indeed some drugs show a 3- or 5-fold increase in their half-life due to such interactions with inhibitors of serotonin reuptake.

Potential clinical scope
Amido-amines won’t obviously alleviate the symptoms of any stroke, as best illustrated within the patient himself by the contrast between the impact on right as compared to left hemianopia. The left occipital lesion was noteworthy by the contrast between the severity of the hemianopia and the limited lesion on anatomical imaging. Accordingly, experimental infarcts in sensory or motor cortex yield long-lasting reduction in neural activity in volumes much larger than the lesion itself. Importantly, the bulk of the left-sided lesion was in white matter, while the visual cortex was largely intact and potentially arousable, as opposed to the right-sided lesion which destroyed the visual cortex, yielding an irreversible deficit. Finally, it is possible that in addition to lesion features, the effect may vary across patients depending on individual polymorphisms of the involved receptors. Indeed, in the past other single-case or small sample studies have reported behavioral benefits from CNS drugs that were not confirmed in large randomized trials.

We believe that the mechanisms underlying the present effect, the conditions for efficacy, and the scope of application deserve further investigation. Patients whose deficit results from a mechanism of disconnection may be the primary beneficiaries of this approach.

Acknowledgments
We thank the patient for his participation. This study was funded by the “Investissements d’avenir” program (ANR-10-IAIHU-06) to the Brain and Spine Institute.

Conflicts of Interest
Laurent Cohen, Amélie Ponchel, Aurélie Kas, Sébastian Ströer, Antoine Del Cul, Guillaume Guérineau de Lamérie, Randa El Hachem, Piirika Crépin, Alexandre Morin declares no conflict of interest.

References
1. Członkowska A, Leśniak M. Pharmacotherapy in stroke rehabilitation. Expert Opin Pharmacother 2009;10:1249–1259.
2. Cohen L, Chaaban B, Habert MO. Transient improvement of aphasia with zolpidem. N Engl J Med 2004;350:949–950.
3. Pollock A, Hazelton C, Henderson C, et al. Interventions for visual field defects in patients with stroke (protocol). Cochrane Database Syst Rev 2010;3:CD008388.
4. Malhotra PA, Parton AD, Greenwood R, Husain M. Noradrenergic modulation of space exploration in visual neglect. Ann Neurol 2006;59:186–190.
5. Paganelli MA, Popescu GK. Actions of bupivacaine, a widely used local anesthetic, on NMDA receptor responses. J Neurosci 2015;35:831–842.
6. Scholz A. Mechanisms of (local) anaesthetics on voltage-gated sodium and other ion channels. Br J Anaesth 2002;89:52–61.
7. Toda S, Sakai A, Ikeda Y, et al. A local anesthetic, ropivacaine, suppresses activated microglia via a nerve growth factor-dependent mechanism and astrocytes via a nerve growth factor-independent mechanism in neuropathic pain. Mol Pain 2011;7:2.
8. Malamed SF. Handbook of local anesthesia-e-book. St. Louis, MO: Elsevier Health Sciences, 2014.
9. Dillane D, Finucane BT. Local anesthetic systemic toxicity. Can J Anaesth 2010;57:368–380.
10. Ferrari L, Crestan V, Sabattini G, et al. Brain penetration of local anaesthetics in the rat: Implications for experimental neuroscience. J Neurosci Methods 2010;186:143–149.
11. Lim J-S, Kang D-W. Stroke connectome and its implications for cognitive and behavioral sequel of stroke. J Stroke 2015;17:256.
12. Feeney DM, Baron JC. Diaschisis.Stroke 1986;17:817–830.
13. Simon MA, Vree TB, Gielen MJ, et al. Similar motor block effects and disposition kinetics between lidocaine and (+/-)mepivacaine in patients undergoing axillary brachial plexus block during day case surgery. Sci World J 2002;2:1306–1319.

14. Lin JH. Tissue distribution and pharmacodynamics: a complicated relationship. Curr Drug Metab 2006;7:39–65.

15. Buccafusco JJ, Letchworth SR, Bencherif M, Lippiello PM. Long-lasting cognitive improvement with nicotinic receptor agonists: mechanisms of pharmacokinetic–pharmacodynamic discordance. Trends Pharmacol Sci 2005;26:352–360.

16. Peng HT, Cheung B. A review of psychophysiological stressors on pharmacokinetics. J Clin Pharmacol 2011;51:1499–1518.

17. McEwen BS, Bowles NP, Gray JD, et al. Mechanisms of stress in the brain. Nat Neurosci 2015;18:1353–1363.

18. Chollet F, Tardy J, Albucher JF, et al. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol 2011;10:123–130.

19. von Moltke LL, Greenblatt DJ, Duan SX, et al. Phenacetin O-deethylation by human liver microsomes in vitro: inhibition by chemical probes, SSRI antidepressants, nefazodone and venlafaxine. Psychopharmacology 1996;128:398–407.

20. Wynn GH, Oesterheld JR, Cozza KL, Armstrong SC. Clinical manual of drug interaction principles for medical practice. Arlington, VA: American Psychiatric Pub, 2009.

21. Anenberg E, Arstikaitis P, Niitsu Y, et al. Ministrokes in channelrhodopsin-2 transgenic mice reveal widespread deficits in motor output despite maintenance of cortical neuronal excitability. J Neurosci 2014;34:1094–1104.

**Supporting Information**

Additional supporting information may be found online in the Supporting Information section at the end of the article.

**Data S1.** All details on MRI and PET-scan imaging methods; figures depicting the duration between successive injections and additional MRI and PET-scan result; tables reporting the full neurovisual assessment, and the detailed results of PET-scan imaging; references of tests used for the neurovisual assessment.

**Figure S1.** (A) Duration of the effect of mepivacaine, as indexed by the lag between successive injections over a period of 2 years. The addition of paroxetine yielded a doubling of the average duration, with an increase in variability. (B) With mepivacaine, there were no substantial changes in the pattern of distant correlation of the lesioned right calcarine region (white). (C) As compared to control subjects, PET-scan showed hypometabolism in the areas affected on anatomical MRI. In the off-mepivacaine state, hypometabolism had an overall larger volume, and extended to apparently intact regions in the left (dotted arrows) and right (solid arrow) occipital cortex. Color scales represent Z scores.

**Figure S2.** The patient’s brain metabolism as assessed with PET-scan, showing hypometabolism mostly visible in the right occipital lobe (white arrow).

**Table S1.** Birmingham object recognition battery.

**Table S2.** PET-scan hypometabolism in the patient as compared to 29 healthy controls.